Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SOD1


Brief Information

Name:Superoxide dismutase
Target Synonym:SOD1,Superoxide Dismutase 1,HSod1,Amyotrophic Lateral Sclerosis 1 (Adult),Epididymis Secretory Protein Li 44,Superoxide Dismutase [Cu-Zn],Cu/Zn Superoxide Dismutase,Indophenoloxidase A,SOD, Soluble,EC,HEL-S-44,IPOA,ALS1,SOD,ALS,Superoxide Dismutase,STAHP,EC:,Superoxide Dismutase 1, Soluble,Superoxide Dismutase, Cystolic,Homodimer
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Synonym Name

SOD1,Superoxide dismutase 1,hSod1


Superoxide dismutase [Cu-Zn] (SOD1) is also known as superoxide dismutase 1 (hSod1), an enzyme that in humans is encoded by the SOD1 gene, located on chromosome 21. SOD1 can bind copper and zinc ions and is one of three superoxide dismutases responsible for destroying free superoxide radicals in the body. The encoded isozyme (SOD1) is a soluble cytoplasmic and mitochondrial intermembrane space protein, acting as a homodimer to convert naturally occurring, but harmful, superoxide radicals to molecular oxygen and hydrogen peroxide. Furthermore, the mutations of SOD1 gene can result in a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Cupric Sulfate/Manganese sulfate/Selenious acid/Zinc Sulfate Approved MULTRYS United States Dietary Supplement American Regent Inc 2020-07-02 Dietary Supplement Details
Orgotein Approved Gt Biopharma Inc Ontosein Spain Rheumatic Diseases; Cystitis; Radiation Injuries null 1996-01-01 Cystitis; Radiation Injuries; Rheumatic Diseases Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
APB-102 APB-102 Phase 1 Clinical University Of Massachusetts Medical School Amyotrophic Lateral Sclerosis Details
AEOL-10150 AEOL-10150 Phase 1 Clinical Aeolus Pharmaceuticals Idiopathic Pulmonary Fibrosis; Neoplasms Details
NI-005 AP-101 (AL-S Pharma); NI-005 Al-S Pharma Ag Details
Manganese sulfate NP-02 Phase 2 Clinical Medesis Pharma Sa Coronavirus Disease 2019 (COVID-19); Radiation Injuries Details
Otaplimastat SP-8203 hydrochloride; SP8203 HCL; SP-8203 Phase 2 Clinical Shin Poong Pharmaceutical Co Ltd Stroke Details
Avasopasem manganese GC-4419; KM-4419; M-40419; SC-72325A Phase 3 Clinical Galera Therapeutics Inc, Metaphore Pharmaceuticals Inc, Activbiotics Pharma Llc Head and Neck Neoplasms; Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Esophagitis; Mouth Neoplasms; Carcinoma, Squamous Cell; Stomatitis; Carcinoma, Non-Small-Cell Lung Details
GC-4711 GC-4711 Phase 2 Clinical Galera Therapeutics Inc Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
BMX-010 BMX-010; MnTE-2-PyP; MnTE-2-PyP5+ Phase 2 Clinical Duke University Acne Vulgaris; Rosacea; Psoriasis; Dermatitis, Atopic Details
Bis-choline tetrathiomolybdate ATN-224; WTX-101; ALXN-1840 Phase 3 Clinical Wilson Therapeutics Hepatolenticular Degeneration; Multiple Myeloma; Prostatic Neoplasms; Melanoma Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message